Kristen Johnson Parker joined Hagens Berman Sobol Shapiro LLP’s Boston office in 2007. She focuses on combatting fraud and anticompetitive conduct within the pharmaceutical industry.
Ms. Parker is currently litigating antitrust cases involving the drugs Flonase, Lipitor, Effexor XR, Wellbutrin XL, and Nexium. In Flonase, pending in the Eastern District of Pennsylvania, Ms. Parker and co-counsel for the direct purchaser class plaintiffs defeated two summary judgment motions, obtained certification of a nationwide class of direct purchasers, and are headed to trial in January 2013. Ms. Parker recently successfully argued against the defendant’s motion to exclude the plaintiffs’ causation expert. In Lipitor, Ms. Parker, along with most of the Boston office, spent over a year researching and drafting the first-filed national antitrust complaint and is currently involved in drafting discovery and opposing motions to dismiss.
Ms. Parker is also instrumental in HBSS’s personal injury cases on behalf of victims who contracted fungal meningitis as a result of receiving contaminated steroid injections manufactured by New England Compounding.
Ms. Parker played a key role on the trial team responsible for the 2010 $142 million civil RICO jury verdict against Pfizer for fraudulently marketing the drug Neurontin. She also oversaw the implementation of the $80 million Vioxx settlement on behalf of litigating third party payers.